We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Device-associated infection and mortality rates, bacterial resistance, and length of stay in hospitals of Malaysia: International Nosocomial Infection Control Consortium (INICC)'s findings.
- Authors
Vineya Rai; Cheong Yuet-Meng; Rosenthal, Victor Daniel; Mohd Shahnaz Hasan; Mazuin Kamarul Zaman; Mansor, Marzida; Sasheela Sri La Sri Ponnampala; Anis Shiham Zainal Abidin; Jegathesan Manikavasagam; Doan Mai Phuong; Nguyen Cia Binh; Lim, Joelene; Kerinjeet Kaur; Othman, Ainul Auzani; Chuah Soo Ling; Chin Seng Gan; Habibah Abdul Aziz; Nor Harlida Abdul Latif; Haryani Che Hamzah; Hasimah Zainol
- Abstract
Background: To report the results of the International Nosocomial Infection Control Consortium (INICC) study conducted in Malaysia from August 2009 through July 2015. Methods: A device-associated healthcare-acquired infection (DA-HAD prospective surveillance study was conducted in 3 adult and 1 pediatric intensive care units (ICUs) from two hospitals, applying the U.S. CDC/NHSN criteria and definitions and INICC methods. Results: There were 2,292 ICU patients documented for 12,932 bed-days. In the medical/surgical ICU the central line-associated bloodstream infection (CLABSI) rate was 9.4 per 1,000 central line-days, the ventilator-associated pneumonia (VAP) rate was 21.2 per 1,000 mechanical ventilator-days, and the catheter-associated urinary tract infection (CAUTI) rate was 5.0 per 1,000 urinary catheter-days. These rates were similar to or higher than the rates of medical/surgical ICUs reported in the INICC international report (4.9 [CLABSI]; 16.5 [VAP]; 5.3 [CAUTI]), and higher than CDC/NHSN reported rates (0.8 [CLABSI]; 1.1 [VAP]; and 1.3 [CAUTID for the medical/surgical ICU. Device utilization ratios in the medical/surgical ICU were higher than INICC and CDC/NHSN reported rates for the same type of ICUs. Resistance of Acinetobacter baumanii to imipenem or meropenem was 30.8%, P. aeruginosa to piperacillin or piperacillin-tazobactam was 10.7%, and K. pneumoniae to ceftriaxone 25.0%. Excess length of stay was 6.4 days for patients with CLABSI, 12.3 for patients with VAP and 0.4 days for patients with CAUTI. Excess crude mortality was 53.1% for CLABSI, 14.8% for VAP and 32.2% for CAUTI. Conclusions: DA-HAI rates in our ICUs are higher than CDC/NSHN rates and INICC international rates.
- Subjects
MALAYSIA; BLOODBORNE infections; CROSS infection; DRUG resistance in microorganisms; LENGTH of stay in hospitals; INTENSIVE care units; LONGITUDINAL method; RESEARCH funding; DESCRIPTIVE statistics; CATHETER-related infections; CATHETER-associated urinary tract infections; VENTILATOR-associated pneumonia
- Publication
Canadian Journal of Infection Control / Revue Canadienne de Prévention des Infections, 2016, Vol 31, Issue 2, p107
- ISSN
1183-5702
- Publication type
Article